DF1001 for Solid Cancers

Recruiting at49 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Dragonfly Therapeutics

Must not be taking: Steroids, Immunosuppressants, Investigational drugs

Disqualifiers: CNS metastases, Autoimmune disease, Serious cardiac illness, others

No Placebo Group

Breakthrough Therapy

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This trial is testing a new treatment called DF1001-001 that helps the immune system target and destroy cancer cells. It focuses on patients with certain types of cancers that have a protein called HER2. The treatment works by activating immune cells to recognize and attack these cancer cells.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any concurrent anticancer treatments or certain other therapies, so it's best to discuss your specific medications with the trial team.

Research Team

Eligibility Criteria

Adults with various advanced solid tumors, especially those expressing HER2. Participants must have measurable disease and adequate organ function, and women of childbearing age must use effective contraception. Excluded are individuals with recent other cancers, CNS metastases, severe heart conditions, uncontrolled infections or allergies to monoclonal antibodies.

Inclusion Criteria

My liver is working well.

I have been treated with trastuzumab, pertuzumab, and a HER2-targeting ADC.

My cancer shows a low level of HER2 protein.

Exclusion Criteria

My heart's pumping ability is significantly reduced.

I have mild side effects from previous treatments, but hair loss and mild nerve issues are okay.

I have not taken any drugs recently that are not allowed in the trial, but I have previously taken HER2-targeting treatments with the required break period.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive increasing doses of DF1001 to determine the maximum tolerated dose

Varies per cohort

Dose Expansion

Participants receive the recommended phase 2 dose (RP2D) of DF1001, either as monotherapy or in combination with other drugs

Up to 24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

28 days after last treatment

Treatment Details

Interventions

• DF1001 (Other)
• Nab paclitaxel (Other)
• Nivolumab (Immunotherapy)

Trial Overview The trial is testing DF1001's ability to activate immune cells against cancer in two phases: dose escalation (finding the right amount) and expansion (testing that amount more broadly). It will be combined with nivolumab or Nab paclitaxel in patients whose tumors express HER2.

Participant Groups

Group I: Monotherapy DF1001 Safety/PK/PD Expansion Experimental Treatment 1 Intervention

Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group II: Monotherapy DF1001 Exploratory Efficacy Expansion in NSCLC Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documentation of HER2 activation.

Group III: Monotherapy DF1001 Exploratory Efficacy Expansion in Metastatic Breast Cancer (HR+/HER2-) Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documentation of HR positive and HER2 negative expression.

Group IV: Monotherapy DF1001 Expansion in Urothelial Bladder Cancer Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group V: Monotherapy DF1001 Expansion in NSCLC Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group VI: Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 Low) Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group VII: Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 High) Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group VIII: Monotherapy DF1001 Expansion in Gastric Cancer Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with gastric cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group IX: Monotherapy DF1001 Expansion in Esophageal Cancer Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 20 patients with esophageal cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group X: Monotherapy DF1001 Expansion in Cancers with Erbb2 Amplification Experimental Treatment 1 Intervention

Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.

Group XI: Monotherapy DF1001 Dose Escalation Experimental Treatment 1 Intervention

Dose escalation cohorts of DF1001 in sequential ascending order.

Group XII: DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HR+/HER2-) Experimental Treatment 2 Interventions

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HR positive and HER2 negative expression.

Group XIII: DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HER2+) Experimental Treatment 2 Interventions

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HER2 positive expression.

Group XIV: Combo Therapy with DF1001 and Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in NSCLC Experimental Treatment 2 Interventions

Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 20 patients, including safety lead-in, with non-small cell lung cancer with documentation of HER2 activation.

Group XV: Combination Therapy with DF1001 and Nivolumab Safety/PK/PD Expansion Experimental Treatment 2 Interventions

Expansion cohort of DF1001 in combination with nivolumab after evaluation for safety in the Combination Therapy with DF1001 and nivolumab Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group XVI: Combination Therapy with DF1001 and Nivolumab Expansion in Urothelial Bladder Cancer Experimental Treatment 2 Interventions

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group XVII: Combination Therapy with DF1001 and Nivolumab Expansion in NSCLC Experimental Treatment 2 Interventions

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group XVIII: Combination Therapy with DF1001 and Nivolumab Expansion in Gastric Cancer Experimental Treatment 2 Interventions

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with gastric cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group XIX: Combination Therapy with DF1001 and Nivolumab Expansion in Esophageal Cancer Experimental Treatment 2 Interventions

Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with esophageal cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.

Group XX: Combination Therapy with DF1001 and Nivolumab Experimental Treatment 2 Interventions

Combination dose escalation of DF1001 in combination with nivolumab in patients with select solid tumors.

Group XXI: Combination Therapy with DF1001 and Nab-paclitaxel Safety/PK/PD Expansion Experimental Treatment 2 Interventions

Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.

Group XXII: Combination Therapy with DF1001 and Nab-paclitaxel Experimental Treatment 2 Interventions

Combination dose escalation of DF1001 in combination with nab-paclitaxel in patients with select solid tumors.

Who Is Running the Clinical Trial?

Dragonfly Therapeutics

Lead Sponsor

Trials

4

Recruited

1,300+